Creo Medical Group PLC represents values such as innovation, integrity, and excellence. The company is dedicated to delivering cutting-edge medical solutions to improve patient outcomes. Creo Medical Group PLC follows a patient-centric approach, ensuring that their products and technologies meet the highest standards of quality and effectiveness. Their corporate philosophy emphasizes the importance of collaboration, research, and development to provide advanced therapeutic solutions in the field of endoscopy and minimally invasive surgery. With a strong focus on continuous improvement and customer satisfaction, Creo Medical Group PLC strives to contribute to the advancement of medical technology for the benefit of patients worldwide.

Creo Medical Group PLC is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United Kingdom, Europe, Asia-Pacific, and North America. With its global presence, Creo Medical Group PLC caters to a wide range of customers and investors across different geographical locations.

Creo Medical Group PLC has achieved significant milestones since its establishment. Some noteworthy achievements include the FDA clearance for their Speedboat RS2 device, allowing the company to enter the US market and expand its customer base. Additionally, Creo Medical Group PLC received CE Mark approval for its CROMA platform, enabling commercialization in the European market. The company also secured key partnerships and collaborations with renowned medical institutions and professionals, highlighting its commitment to innovation and development in the medical device sector. With these milestones, Creo Medical Group PLC has established itself as a leading player in the field, dedicated to improving patient outcomes through advanced technology.

Creo Medical Group PLC, a leading medical device company based in the UK, was founded in 2003. The company specializes in the development and commercialization of advanced surgical instruments. Creo Medical has a strong focus on non-invasive surgical technologies that provide effective treatments with minimal patient discomfort and enhanced recovery. With a talented team of professionals, Creo Medical has achieved significant milestones in its history, including the successful launch of its flagship device, the CROMA™ Advanced Energy Platform. The company is committed to driving innovation in the medical field, working towards improving patient outcomes and revolutionizing surgical procedures globally. Creo Medical Group PLC continues to grow and establish a strong presence in the market through its dedication to research, development, and commercialization of cutting-edge medical devices.

The main competitors of Creo Medical Group PLC in the market are (insert competitor names here).

Creo Medical Group PLC is primarily active in the medical technology industry.

The business model of Creo Medical Group PLC revolves around developing and commercializing medical devices for surgical endoscopy. Creo Medical specializes in advanced energy devices and aims to provide innovative solutions for minimally invasive procedures, such as radiofrequency ablation and microwave coagulation. By leveraging its proprietary technology, Creo Medical aims to enable healthcare professionals to improve patient outcomes, minimize complications, and reduce healthcare costs. With a focus on enhancing clinical capabilities and expanding its product portfolio, Creo Medical Group PLC continues to drive innovation in the medical device industry.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Creo Medical Group.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Creo Medical Group.

Το AlleAktien Qualitätsscore για το Creo Medical Group είναι 5/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Creo Medical Group.

Τα κέρδη για τον Creo Medical Group δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Creo Medical Group PLC is a British medical technology company that specializes in the development and marketing of advanced medical technologies for endoscopy. The company was founded in 2003 and is headquartered in Chepstow, Wales.

Η Creo Medical Group καταβάλλει μια διανομή της τάξεως των 0 GBP διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Creo Medical Group αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Creo Medical Group είναι GB00BZ1BLL44.

Το WKN της Creo Medical Group είναι A2DH40.

Ο τίκερ της Creo Medical Group είναι CREO.L.

Κατά τους τελευταίους 12 μήνες η Creo Medical Group κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Creo Medical Group προβλέπεται να πληρώσει μέρισμα 0 GBP.

Η απόδοση μερίσματος της Creo Medical Group ανέρχεται σήμερα στο .

Creo Medical Group πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Creo Medical Group πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 GBP. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Creo Medical Group ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Creo Medical Group από την 24/12/2024 με τιμή 0 GBP, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 24/12/2024.

Η τελευταία μερίσματος έγινε στις 24/12/2024.

Το έτος 2023, η Creo Medical Group διένειμε 0 GBP ως μερίσματα.

Τα μερίσματα του Creo Medical Group καταβάλλονται σε GBP.